Since mutations in the MAPK/ERK pathways are common in both borderline and low-grade ovarian cancer and luminal breast cancers the presence of KRAS and BRAF mutations was investigated among the ovarian tumors [23], [24]. The gene discussed is BRAF; the disease is ovarian neoplasm.